share_log

Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.

Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.

祁連國際控股集團有限公司宣佈更名爲BGm集團有限公司。
PR Newswire ·  10/29 20:00

CHENGDU, China, Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective on October 30, 2024, the Company will change its name to "BGM Group Ltd." In connection with the name change, the trading symbol of the Company's Class A ordinary shares has been changed to "BGM" on the Nasdaq Stock Market, effective on August 11, 2024, and the CUSIP number remains unchanged.

中國成都,2024年10月29日 /PRNewswire/ — 啓聯國際控股集團有限公司(「啓聯」 或 「公司」)(納斯達克股票代碼:BGM)欣然宣佈,自2024年10月30日起,該公司將更名爲 「BgM 集團有限公司」。與名稱變更有關的是,公司在納斯達克股票市場上的A類普通股的交易代碼已更改爲 「BGM」,自2024年8月11日起生效,CUSIP編號保持不變。

About Qilian International Holding Group Ltd.

關於啓聯國際控股集團有限公司

BGM Group Ltd., formerly known as Qilian International Holding Group Ltd., headquartered in Chengdu, China, is an innovative company dedicated to the fields of biopharmaceuticals, bio-extraction, and medical health. Our current product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. The oxytetracycline API not only provides raw materials for pharmaceutical companies to produce human antibiotics but also supports the global breeding and livestock industries to ensure the safety of poultry and seafood. The crude heparin sodium, after processing by downstream companies, is transformed into refined heparin sodium and heparin sodium injection solutions, which are major anticoagulants. Licorice preparations, such as compound licorice lozenges, are used as cough suppressants and supplied to retail pharmacies. For more information, visit the Company's website at: .

BgM Group Ltd.,前身爲啓聯國際控股集團有限公司,總部位於中國成都,是一家致力於生物製藥、生物提取和醫療健康領域的創新公司。我們目前的產品範圍包括土黴素原料藥、甘草製劑和粗肝素鈉。土黴素API不僅爲製藥公司生產人類抗生素提供原料,還支持全球育種和畜牧業,確保家禽和海鮮的安全。粗肝素鈉經下游公司加工後,轉化爲精製肝素鈉和肝素鈉注射液,它們是主要的抗凝劑。甘草製劑,例如複方甘草潤喉糖,用作止咳劑,供應給零售藥房。欲了解更多信息,請訪問該公司的網站:。

Safe Harbor Statement

安全港聲明

Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are the ability to manage growth; ability to identify and integrate other future acquisitions; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting our profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

本新聞稿中的某些聲明是1995年《美國私人證券訴訟改革法》的 「安全港」 條款所指的 「前瞻性聲明」。在本新聞稿中使用時,「估計」、「預測」、「預期」、「預測」、「計劃」、「打算」、「相信」、「尋求」、「可能」、「將」、「應該」、「未來」、「提議」 等詞語以及這些詞語或類似表述的變體(或此類詞語或表達的否定版本)旨在識別前瞻性陳述。這些前瞻性陳述不能保證未來的業績、狀況或業績,涉及許多已知和未知的風險、不確定性、假設和其他重要因素,其中許多因素是公司無法控制的,可能導致實際業績或結果與前瞻性陳述中討論的結果存在重大差異。除其他外,重要因素包括管理增長的能力;識別和整合其他未來收購的能力;未來獲得額外融資爲資本支出提供資金的能力;總體經濟和商業狀況的波動;成本或其他對我們的盈利能力產生不利影響的因素;涉及專利、知識產權和其他事項的訴訟;立法和監管環境的潛在變化;疫情或疫情。本新聞稿中包含的前瞻性陳述還受到其他風險和不確定性的影響,包括公司向美國證券交易委員會提交的文件中更全面描述的風險和不確定性,這些文件可在www.sec.gov上進行審查。除非適用法律要求,否則公司沒有義務更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。此類信息僅說明截至本新聞稿發佈之日。

For investor and media inquiries, please contact:
info@qiliancorp.com, jiangyubin@qiliancorp.com or xinchen@qiliancorp.com

投資者和媒體垂詢,請聯繫:
info@qiliancorp.com、jiangyubin@qiliancorp.com 或 xinchen@qiliancorp.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論